Human anti-Mullerian hormone(AMH) ELISA Kit

Name: Human anti-Mullerian hormone(AMH) ELISA Kit
SKU: DEIA-Z00113
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Species Reactivity

Human

Contents of Kit

1. Antibody coated wells: 1 plates of 96 breakable wells (12 strips x 8 wells) coated with anti-MHA monoclonal antibody and blocked.
2. Standard: A serial diluted standard (ng/mL): 2400, 600, 150, 37.5, 9.375, 2.34, 0.586, 0(blank). Spin before use.
3. The storage standard is 4μg/μL, diluted with Diluent 1 in 3-fold dilution.
4. Detection Antibody (200X): 70 μL of 200X concentrated detection antibody, diluted with Diluent 2, Spin before use.
5. Second antibody (3000X): Goat anti-rabbits POD labeled antibody, 1: 3000 diluted with Diluent 2. Spin before use.
6. Diluent 1: 12 mL, used to diluent the Standard and samples.
7. Diluent 2: 2 bottle (12 mL/bottle), used to diluent the Detection antibody and second antibody.
8. Wash Concentrate (50X): 2 bottle, 15 mL/bottle of 50X concentrated detergent solution.
9. TMB One-Step Substrate Reagent: 2 bottle, 15 mL/bottle of TMB Substrate reagent.
10. Stop Solution: 2 bottle, 15 mL/bottle of 0.18M acid buffer.
11. Plate Sealers: 3 sheets with adhesive backing.

Storage

For more detailed information, please download the following document on our website.

General Description

Anti-Müllerian hormone also known as AMH is a protein that, in humans, is encoded by the AMH gene.It inhibits the development of the Müllerian ducts (paramesonephric ducts) in the male embryo. It has also been called Müllerian inhibiting factor (MIF), Müllerianinhibiting hormone (MIH), and Müllerian-inhibiting substance (MIS). AMH is a protein hormone structurally related to inhibin and activin, and a member of the transforming growth factor-β (TGF-β) family. It is a dimeric glycoprotein that has a molar mass of 140 kDa. AMH is secreted by Sertoli cells of the testes during embryogenesis of the fetal male. In females, it is secreted by the granulosa cells of ovarian follicles. In mammals, AMH prevents the development of the müllerian ducts into the uterus and other müllerian structures. The effect is ipsilateral, that is each testis suppresses Müllerian development only on its own side. In
humans, this action takes place during the first 8 weeks of gestation. AMH is expressed by granulosa cells of the ovary during the reproductive years, and controls the formation of primary follicles by inhibiting excessive follicular recruitment by FSH.

Citations

Have you cited DEIA-Z00113 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Evaluation of relationship between HbA1c levels and ovarian reserve in patients with type 1 diabetes mellitus

GYNECOLOGICAL ENDOCRINOLOGY

Authors: Kadirogullari, Pinar; Demir, Esra; Banat, Pinar Yalcin; Kiyak, Huseyin; Seckin, Kerem Doga

Abstract

In organ or non-organ-specific autoimmune disorders, human ovary is usually the target of the autoimmune attack. We aimed to demonstrate the correlation between ovarian reserve and DM1, based on the view that women with type-1 diabetes mellitus (DM1) will have lower AMH levels secondary to poor glycemic control and autoimmune attacks. Ovarian functions of 42 patients diagnosed with DM1 who use insulin and 65 healthy volunteers were analyzed. Basal hormone and AMH levels were measured during the follicular phase. Fasting and postprandial blood glucose concentrations, HbA1c and C-peptide levels were evaluated. The mean antral follicle count (AFC) was significantly lower in DM1 patients than in healthy controls (p = .001). The AMH levels were lower in women with DM1 than in the controls (p = .001). The HbA1c values of DM1 patients, who formed the study group, was significantly higher than the control group. Ovarian reserve that is evaluated with serum AMH level is affected by poor glycemic control in type 1 diabetes. Due to the time of the autoimmune damage in the ovaries and the observable effects of this damage, more comprehensive and longer-term studies are needed to be conducted for the follow-up of reproductive abnormalities.

A case of equine cryptorchidism with undetectable serum anti-Mullerian hormone

JOURNAL OF VETERINARY MEDICAL SCIENCE

Authors: Murase, Harutaka; Ochi, Akihiro; Tozaki, Teruaki; Kakoi, Hironaga; Munkhtuul, Tsogtgerel; Kurimoto, Shinjiro; Sato, Fumio; Hada, Tetsuro

Abstract

Serum anti-Mullerian hormone (AMH), a marker of equine cryptorchidism, is detectable in intact and cryptorchid stallions but not in geldings because it is secreted from Sertoli cells. A 4-year-old uncastrated Thoroughbred racehorse had no visible testes; therefore, the horse was considered a bilateral cryptorchidism. However, the serum AMH was undetectable (<0.08 ng/ml). Human chorionic gonadotrophin (hCG) stimulating test result indicated that the horse was a gelding. The results of sex chromosomal analysis and sequence analysis of SRY gene suggested that the horse was a genetically-intact stallion (X/Y). Only one small degenerative testis was present in the abdominal cavity. The reasons of undetectable serum AMH levels and negative response to hCG stimulation might be low numbers of Sertoli and Leydig cells. This study reports a case of serum AMH-undetectable cryptorchid stallion.